Finance

Lists
Q3 2026 earnings • in 3 days
See details
DNA:NYSE
Ginkgo Bioworks Holdings Inc
$9.85
-12.33%
(-1.38) 1D
$9.88
+0.30% (+0.030)
After hours
Closed: Nov 2, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNA...
Open
$11.35
High
$11.35
Low
$9.28
Mkt. cap
633.75M
Avg. vol.
3.34M
Volume
3.55M
52-wk high
$18.22
52-wk low
$5.37
EPS
-$5.00
Beta
1.79
Shares outstanding
55.38M
No. of employees
485
Open
$11.35
High
$11.35
Low
$9.28
Mkt. cap
633.75M
Avg. vol.
3.34M
Volume
3.55M
52-wk high
$18.22
52-wk low
$5.37
EPS
-$5.00
Beta
1.79
Shares outstanding
55.38M
No. of employees
485
News stories
From web sources and news partners
Profile
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
About Ginkgo Bioworks Holdings Inc
CEOJason Kelly
Employees485
Founded2008
HeadquartersBoston, Massachusetts, United States
SectorHealth care
Websiteginkgo.bio
Analyst ratings
Based on 3 analysts giving stock ratings to DNA in the past 3 months
Sell
Buy
0
Hold
1
Sell
2
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for DNA in the last 3 months.
Highest
Current $9.85
$11.00 (+11.68%)
Average
$8.00 (-18.78%)
Lowest
$5.00 (-49.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brendan Smith
TD Cowen
Hold
Maintained
$11.00
+11.7%
10/13/2026
Mark Massaro
BTIG
Sell
Reiterated
$5.00
-49.2%
09/04/2026
Jared Haase
William Blair
Sell
Maintained
-
-
08/13/2026
Matt Larew
William Blair
Sell
Reiterated
-
-
05/11/2026
Next call in 3 days
Thu, Nov 5, 4:30 PM
Fiscal period
Q3 2026
- / -$0.54
Revenue / Est. (USD)
- / 21.51M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
38.84M
33.40M
19.47M
20.16M
Cost of goods sold
12.80M
7.30M
3.10M
1.72M
Cost of revenue
12.80M
7.30M
3.10M
1.72M
Research and development expenses
69.35M
50.13M
49.92M
46.21M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
44.95M
46.01M
37.83M
29.67M
Operating expense
114.31M
96.14M
87.75M
75.88M
Total operating expenses
127.11M
103.44M
90.85M
77.60M
Operating income
-88.27M
-70.05M
-71.37M
-57.44M
Other non operating income
-163.00K
821.00K
-388.00K
809.00K
EBT including unusual items
-80.75M
-81.39M
-76.14M
-57.19M
EBT excluding unusual items
-82.69M
-62.01M
-68.17M
-58.07M
Income tax expense
1.00K
-643.00K
-80.00K
128.00K
Effective tax rate
-
0.79%
0.10%
-0.22%
Other operating expenses
-
-
-
-
Net income
-80.76M
-80.75M
-82.59M
-46.71M
Net profit margin
-207.93%
-241.80%
-424.09%
-231.74%
Earnings per share
-
-0.77
-
-0.73
Interest and investment income
5.74M
7.21M
3.60M
3.23M
Interest expense
-
-
-
-
Net interest expenses
5.74M
7.21M
3.60M
3.23M
Depreciation and amortization charges
-
-
-
-
EBITDA
-88.10M
-61.08M
-62.78M
-49.23M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps